- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
New drug trial for Bullous Pemphigoid
Nottingham, England - A five-year 'BLISTER' study is being coordinated by two universities, as they are seeking 250 bullous pemphigoid sufferers to participate in a randomized trial, according to Media-Newswire.
Nottingham, England
- A five-year 'BLISTER' study is being coordinated by two universities, as they are seeking 250 bullous pemphigoid sufferers in the UK and Germany to participate in a randomized trial, according to Media-Newswire.
Half of participants will be treated with the current standard steroid drug, prednisolone, and the other half with doxycycline. Each participant will be followed for one year to see if doxycycline is more effective than prednisolone, but with fewer side effects.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
